Sairopa B.V.
Sairopa B.V. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Sairopa B.V..
Sairopa B.V. is a company.
Key people at Sairopa B.V..
Key people at Sairopa B.V..
Sairopa B.V. is a clinical-stage biotech company headquartered in Rotterdam, Netherlands, focused on developing novel cancer immunotherapies by modulating the patient's immune system to enhance anti-tumor responses.[1][3][8] Its pipeline includes ADU-1805 (anti-SIRPα antibody in Phase 1 for advanced solid tumors), ADU-1604 (anti-CTLA4 antibody, Phase 1 completed for PD-1 relapsed/refractory melanoma with Phase 2 planned for 2025), and a preclinical SIRPαxPD-L1 bispecific antibody targeting an IND filing in 2026.[1][3][7] The company serves oncology patients with hard-to-treat cancers, addressing immune suppression mechanisms that limit current therapies' efficacy, and demonstrates growth through partnerships like a $40M upfront and $35M milestone from Exelixis in 2024.[3][7]
Incorporated in 2021 and backed by Van Herk Investments, Sairopa has advanced rapidly, acquiring key assets and achieving clinical milestones that validate its proprietary antibody platforms.[2][5][6]
Sairopa B.V. was incorporated in 2021 in Rotterdam, Netherlands, entering the cancer immunotherapy space through a strategic acquisition backed by Van Herk Investments, a life sciences-focused investor.[2][5][6] In April 2021, Sairopa purchased a portfolio of non-renal therapeutic antibodies from Chinook Therapeutics, Inc., including assets originally from BioNovion/Aduro Biotech, which propelled it into clinical development.[5][6] This move followed Novartis's 2023 acquisition of Chinook for renal assets, leading to the divestment of Sairopa shares, which Van Herk Investments fully acquired in March 2024 to sustain momentum.[5]
The company's emergence capitalized on prior research into immune-modulating antibodies like anti-SIRPα (e.g., Voets et al., 2019), transforming preclinical promise into a robust pipeline with early clinical traction, including Phase 1 initiations and partnership deals.[3][6]
Sairopa rides the wave of next-generation immunotherapy, targeting "don't eat me" signals like SIRPα to overcome resistance in solid tumors, a key trend as PD-1 inhibitors plateau in efficacy for many cancers.[1][3] Timing aligns with surging demand for combo-immune therapies amid a post-2020 biotech resurgence in antibody engineering, bolstered by AI-driven discovery and bispecifics.[1][7] Market forces favor it: rising incidence of immunotherapy-resistant neoplasms, investor interest in clinical-stage assets (e.g., Van Herk's life sciences portfolio), and Big Pharma scouting (Exelixis option).[3][5][7] Sairopa influences the ecosystem by licensing proven assets to accelerate validation, potentially expanding Dutch biotech's global footprint in oncology.[5]
Sairopa's trajectory points to Phase 2 readouts for ADU-1604 in 2025 and IND for its bispecific in 2026, with Exelixis's option decision hinging on Phase 1 data—success could trigger licensing and commercialization.[3][7] Trends like bispecific antibodies and combo regimens will shape its path, amplifying impact if partnerships scale. Its influence may grow via Van Herk support, positioning it as a nimble player in immune-oncology innovation, much like its origin acquisition turned dormant assets into clinical contenders.[5][6]
